Biogen (BIIB)
196.45
+0.49 (0.25%)
Upcoming Events
Latest Headlines
Biogen's salanersen gets FDA breakthrough therapy designation for SMA
June 4, 2026 7:30 AM - StreetInsider
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
June 4, 2026 7:30 AM - StreetInsider
UCB and Biogen report positive results for lupus drug dapirolizumab pegol
June 4, 2026 5:54 AM - StreetInsider
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
June 4, 2026 1:00 AM - StreetInsider
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
May 28, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Raised to $227 at RBC Capital
May 27, 2026 5:42 AM - StreetInsider
Biogen and Denali discontinue Parkinson's drug after trial fails
May 21, 2026 6:00 PM - StreetInsider
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 21, 2026 6:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $225 at Piper Sandler
May 15, 2026 8:11 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Biogen (BIIB)
May 15, 2026 6:38 AM - StreetInsider
Evercore ISI Reinstates Biogen (BIIB) at Outperform
May 14, 2026 4:59 PM - StreetInsider
Biogen (BIIB) PT Raised to $300 at Oppenheimer
May 14, 2026 12:04 PM - StreetInsider
Jefferies: 'we think BIIB stock could climb higher on the resiliency of the commercial franchise'
May 14, 2026 8:35 AM - StreetInsider
Form 8-K BIOGEN INC. For: May 14
May 14, 2026 8:31 AM - SEC Filing
Mizuho Reiterates Outperform Rating on Biogen (BIIB)
May 14, 2026 8:17 AM - StreetInsider
Wolfe Research on Biogen (BIIB): 'Re-mem-BIIB-er This Day, BIIB Is Moving Tau Forward'
May 14, 2026 7:44 AM - StreetInsider
Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'
May 14, 2026 7:29 AM - StreetInsider
Biogen stock jumps 10% on positive phase 2 diranersen data for Alzheimer’s
May 14, 2026 7:16 AM - StreetInsider
Biogen's diranersen shows tau reduction in Alzheimer's trial
May 14, 2026 6:59 AM - StreetInsider
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026 6:59 AM - Globe NewsWire
CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities
May 11, 2026 8:30 AM - Globe NewsWire
FDA extends review period for Eisai's LEQEMBI subcutaneous injection
May 8, 2026 2:30 AM - StreetInsider
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease
May 8, 2026 2:30 AM - PR NewsWire
Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600
May 7, 2026 6:02 PM - PR NewsWire
Bright Horizons Family Solutions and Remitly Global to Join S&P SmallCap 600
May 7, 2026 5:18 PM - StreetInsider
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
May 7, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A BIOGEN INC. Filed by: FMR LLC
May 6, 2026 11:01 AM - SEC Filing
Form 4 BIOGEN INC. For: May 01 Filed by: Keeney Adam
May 5, 2026 4:12 PM - SEC Filing
Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, Talent
May 5, 2026 6:37 AM - BizWire
Freedom Broker Upgrades Biogen (BIIB) to Buy, raises PT to $245
May 1, 2026 1:05 PM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Biogen (BIIB)
May 1, 2026 6:52 AM - StreetInsider
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
April 30, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Raised to $190 at Truist Securities
April 30, 2026 4:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $222 at RBC Capital
April 30, 2026 8:28 AM - StreetInsider
Biogen (BIIB) PT Raised to $196 at Wedbush
April 30, 2026 8:26 AM - StreetInsider
Biogen (BIIB) PT Raised to $206 at Morgan Stanley
April 30, 2026 7:57 AM - StreetInsider
Biogen (BIIB) PT Lowered to $200 at Bernstein SocGen Group
April 30, 2026 7:35 AM - StreetInsider
Biogen (BIIB) PT Raised to $260 at Guggenheim
April 30, 2026 6:41 AM - StreetInsider
Form SCHEDULE 13G BIOGEN INC. Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 5:02 PM - SEC Filing
Biogen (BIIB) PT Raised to $203 at BofA Securities
April 29, 2026 2:58 PM - StreetInsider
Biogen shares rise after Q1 beat; full-year profit outlook slashed
April 29, 2026 6:55 AM - StreetInsider
Form 10-Q BIOGEN INC. For: Mar 31
April 29, 2026 6:41 AM - SEC Filing
Form 8-K BIOGEN INC. For: Apr 29
April 29, 2026 6:11 AM - SEC Filing
Biogen (BIIB) Tops Q1 EPS by 62c; cuts EPS guidance
April 29, 2026 6:05 AM - StreetInsider
Form ARS BIOGEN INC. For: Dec 31
April 28, 2026 4:47 PM - SEC Filing
Form DEFA14A BIOGEN INC.
April 28, 2026 4:43 PM - SEC Filing
Form DEF 14A BIOGEN INC. For: Jun 09
April 28, 2026 4:35 PM - SEC Filing
Truist Securities Reiterates Hold Rating on Biogen (BIIB)
April 27, 2026 9:45 AM - StreetInsider
U.S. Biotech stocks: Q1 earnings previews
April 26, 2026 8:00 PM - StreetInsider
Biogen (BIIB) PT Raised to $200 at BofA Securities
April 24, 2026 3:38 PM - StreetInsider
Biogen (BIIB) PT Raised to $185 at JPMorgan
April 23, 2026 8:27 AM - StreetInsider
UBS upgrades Biogen, sees up to 50% upside on pipeline catalysts
April 22, 2026 9:53 AM - StreetInsider
UBS Upgrades Biogen (BIIB) to Buy
April 22, 2026 2:46 AM - StreetInsider
Biogen acquires TJ Biopharma's felzartamab rights in China for $850M
April 20, 2026 7:31 AM - StreetInsider
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026 7:30 AM - Globe NewsWire
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
April 20, 2026 7:30 AM - PR NewsWire
Wells Fargo Upgrades Biogen (BIIB) to Overweight
April 20, 2026 5:14 AM - StreetInsider
Piper Sandler Upgrades Biogen (BIIB) to Overweight
April 13, 2026 5:05 PM - StreetInsider
Biogen (BIIB) PT Lowered to $189 at Truist Securities
April 13, 2026 7:09 AM - StreetInsider
Biogen (BIIB) PT Raised to $200 at Morgan Stanley
April 10, 2026 8:15 AM - StreetInsider
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
April 8, 2026 4:01 PM - BizWire
Stoke Therapeutics adds Clare Kahn to board of directors
April 7, 2026 4:01 PM - StreetInsider
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
April 7, 2026 4:01 PM - BizWire
Biogen (BIIB) PT Lowered to $213 at RBC Capital
April 7, 2026 9:02 AM - StreetInsider
Biogen expects $34 million charge in first quarter 2026
April 6, 2026 6:36 AM - StreetInsider
Form 8-K BIOGEN INC. For: Apr 06
April 6, 2026 6:32 AM - SEC Filing
Form 4 BIOGEN INC. For: Apr 01 Filed by: Godbout Sean
April 3, 2026 4:06 PM - SEC Filing
Biogen (BIIB) PT Raised to $237 at H.C. Wainwright
April 2, 2026 6:42 AM - StreetInsider
Biogen (BIIB) PT Raised to $275 at Oppenheimer
April 1, 2026 8:07 AM - StreetInsider
Biogen (BIIB) PT Raised to $245 at Canaccord
April 1, 2026 7:10 AM - StreetInsider
Form 8-K BIOGEN INC. For: Mar 31
March 31, 2026 5:03 PM - SEC Filing
William Blair on Biogen (BIIB): 'we see potential to add $1.54 billion in sales' through APLS deal
March 31, 2026 3:28 PM - StreetInsider
Guggenheim Reiterates Buy Rating on Biogen (BIIB) following Apellis deal
March 31, 2026 1:28 PM - StreetInsider
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
March 31, 2026 11:55 AM - StreetInsider
Biogen (BIIB) call put ratio 1.6 calls to 1 put after acquiring Apellis (APLS)
March 31, 2026 10:15 AM - StreetInsider
Barclays on Biogen (BIIB): Apellis deal 'signals confidence' ahead of felzartamab readouts
March 31, 2026 9:47 AM - StreetInsider
Stifel on Biogen (BIIB): Apellis acquisition 'surprising,' but makes sense given move towards rare kidney
March 31, 2026 9:42 AM - StreetInsider
BMO Capital on Biogen (BIIB): Apellis deal 'sets a clear path for further expansion in nephrology'
March 31, 2026 9:36 AM - StreetInsider
Biogen to acquire Apellis for $5.6 billion in cash deal
March 31, 2026 6:59 AM - StreetInsider
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026 6:59 AM - StreetInsider
Biogen to acquire Apellis Pharmaceuticals for $5.6 billion or $41/sh plus CVR
March 31, 2026 6:45 AM - StreetInsider
BofA Securities on Biogen (BIIB): 'clear positive trend in execution'
March 30, 2026 4:41 PM - StreetInsider
Biogen will introduce 28 mg vial at same price as 12 mg vial, resulting in parity pricing for patients in the maintenance phase - Spokesperson
March 30, 2026 10:36 AM - StreetInsider
BMO Capital Reiterates Market Perform Rating on Biogen (BIIB)
March 30, 2026 9:31 AM - StreetInsider
Morgan Stanley Reiterates Equalweight Rating on Biogen (BIIB)
March 30, 2026 9:25 AM - StreetInsider
Jefferies Reiterates Buy Rating on Biogen (BIIB) following FDA approval of HD Spinraza for SMA
March 30, 2026 9:24 AM - StreetInsider
FDA approves high dose SPINRAZA for spinal muscular atrophy
March 30, 2026 7:30 AM - StreetInsider
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
March 30, 2026 7:30 AM - StreetInsider
Biogen reports positive phase 2 results for lupus skin drug
March 28, 2026 3:00 PM - StreetInsider
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Acti
March 28, 2026 3:00 PM - StreetInsider
Form SCHEDULE 13G/A BIOGEN INC. Filed by: VANGUARD GROUP INC
March 26, 2026 4:10 PM - SEC Filing
LEQEMBI shows high treatment persistence in real-world study
March 20, 2026 12:13 PM - StreetInsider
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
March 20, 2026 12:05 PM - PR NewsWire
Securities Litigation on Behalf of Purchasers of Biogen, Inc. Securities (BIIB) Certified as Class Action
March 19, 2026 8:00 AM - Globe NewsWire
Biogen to present litifilimab lupus data at dermatology meeting
March 19, 2026 7:30 AM - StreetInsider
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
March 19, 2026 7:30 AM - StreetInsider
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Biogen (BIIB) PT Raised to $150 at HSBC
March 17, 2026 3:39 AM - StreetInsider
Form 8-K BIOGEN INC. For: Mar 11
March 11, 2026 5:28 PM - SEC Filing
Oppenheimer Reiterates Outperform Rating on Biogen (BIIB): "continue to view SMA as an important franchise"
March 11, 2026 4:54 PM - StreetInsider
Biogen reports positive salanersen trial results in SMA patients
March 11, 2026 8:00 AM - StreetInsider
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
March 11, 2026 8:00 AM - StreetInsider
Full Article List
